Privo Technologies, Inc. Awarded $2.5M from National Cancer Institute for its Intraoperative Treatment of Solid Tumors
Privo Technologies, Inc. (“Privo”, “the Company”), a clinical stage biopharmaceutical company focused on optimizing state-of-the-art oncology treatments announced today that it has received $2.5M grant as part of National Cancer Institute’s Notice of Special Interest announcement.
The award supports the first-in-man clinical study of Privo’s PRV211 Intraoperative Anti-Cancer Treatment. It is used for all solid tumors to eliminate any remining cancer cells post-surgical resection. The intraoperative treatment would be applied to the tumor bed immediately following tumor resection to eliminate micrometastases and treat nearby lymph nodes. PRV211 is a sterile derivative of the PRV nanoengineered platform technology which safely and effectively deliver locoregional anticancer treatments.
“Privo Technologies is thankful for the continued support by the NCI in the development of the PRV Platform,” said Manijeh Goldberg, PhD, CEO of Privo Technologies, Inc. “Privo Technologies seeks to transform the standard of care for treating solid tumors. Surgeons have a challenging balancing act – cut out too much and damage functionality, remove too little and risk leaving tumor cells behind.”
Companies In This Post
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more